Literature DB >> 21470874

RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.

Daniel Schramek1, Verena Sigl, Josef M Penninger.   

Abstract

The receptor activator of nuclear factor-κB (RANK) and its ligand RANKL are best known for their essential function in bone remodeling and bone-related pathologies such as osteoporosis and arthritis. In humans, dysregulation of the RANK-RANKL system is the major cause of osteoporosis in postmenopausal women. Furthermore, appropriate RANKL signaling is also required for the formation of a lactating mammary gland. Both RANKL and RANK are expressed by mammary epithelial cells under the control of sex hormones. Recent data also indicate that RANK and RANKL control the preferential metastasis of breast cancer cells to the bone as well as sex hormone-driven primary mammary cancer. Here we critically review these data with special attention on mammary cancer development.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470874     DOI: 10.1016/j.tem.2011.02.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  23 in total

Review 1.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 2.  Role of RANKL in cancer development and metastasis.

Authors:  Kazuo Okamoto
Journal:  J Bone Miner Metab       Date:  2021-01-02       Impact factor: 2.626

Review 3.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

4.  Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?

Authors:  Olivier Micheau; Florent Dufour; Henning Walczak
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 5.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

6.  RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells.

Authors:  Yuvaraj Sambandam; Sashank Sakamuri; Sundaravadivel Balasubramanian; Azizul Haque
Journal:  J Cell Biochem       Date:  2016-01       Impact factor: 4.429

7.  Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.

Authors:  Carolyn J Crandall; Aaron K Aragaki; Jane A Cauley; Anne McTiernan; Joann E Manson; Garnet L Anderson; Jean Wactawski-Wende; Rowan T Chlebowski
Journal:  Breast Cancer Res Treat       Date:  2011-10-07       Impact factor: 4.872

Review 8.  Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?

Authors:  Heidi N Hilton; J Dinny Graham; Christine L Clarke
Journal:  Mol Endocrinol       Date:  2015-08-12

Review 9.  Role of RANKL/RANK in primary and secondary breast cancer.

Authors:  Toshiyuki Yoneda; Soichi Tanaka; Kenji Hata
Journal:  World J Orthop       Date:  2013-10-18

10.  Emerging Functions of RANKL in Lymphoid Tissues.

Authors:  Christopher G Mueller; Estelle Hess
Journal:  Front Immunol       Date:  2012-09-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.